Bacil Pharma Ltd shareholder Manubhai Shah sells 394,893 shares, stake falls to 10.02%

What Bacil Pharma announced

Bacil Pharma Ltd filed a disclosure with the Bombay Stock Exchange on 25 June 2026 under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The filing records an open‑market sale of shares by Mr. Manubhai Amrutlal Shah, an individual investor who is not part of the promoter group.

"The share disposal was effected on 23‑24 June 2026, reducing the acquirer’s holding from 12.77% to 10.02% of the total voting capital."

The filing provides a detailed breakdown of the shareholding before and after the transaction, the mode of acquisition, and confirms that the company’s equity share capital remains unchanged.

Details of the share sale

• Acquirer / Person Acting in Concert (PAC): Manubhai Amrutlal Shah
• Relationship to promoters: No (the acquirer does not belong to the promoter group)
• Mode of transaction: Open‑market purchase/sale
• Dates of transaction: 23 June 2026 and 24 June 2026
• Number of shares sold: 394,893 equity shares
• Shareholding before sale: 1,831,709 shares, representing 12.77% of the total voting capital
• Shareholding after sale: 1,436,816 shares, representing 10.02% of the total voting capital
• Total equity share capital of Bacil Pharma: 1,43,53,000 equity shares of Rs 10 each (unchanged)
• Diluted share/voting capital after sale: Not applicable / not disclosed

The filing shows the same total number of equity shares before and after the transaction, indicating that the sale did not involve any issuance of new shares, conversion of convertible securities, or any other capital‑raising activity.

Key facts at a glance

Why this matters for investors

The disclosure is a statutory requirement when an investor’s shareholding crosses the thresholds set by SEBI for substantial acquisition or disposal. While the sale does not alter Bacil Pharma’s capital structure, it does reduce the voting power of a significant non‑promoter shareholder. For existing shareholders, the key implications are:

• No dilution: Since no new shares were issued, the proportionate ownership of all other shareholders remains the same.
• Change in share‑holding pattern: A reduction from 12.77% to 10.02% may affect the balance of power among large shareholders, especially if other entities increase their stakes.
• Regulatory compliance: The filing confirms that the transaction complies with SEBI’s disclosure norms, providing transparency to the market.
• No immediate financial impact: The filing does not disclose any cash consideration received, nor does it indicate any change in the company’s financial position.

Investors should monitor subsequent filings for any further changes in the shareholding pattern, especially if other large shareholders make acquisitions or disposals.

Conclusion

Manubhai Amrutlal Shah’s open‑market sale of 394,893 Bacil Pharma shares on 23‑24 June 2026 reduced his stake from 12.77% to 10.02%. The transaction was disclosed in compliance with SEBI Regulation 29(2) on 25 June 2026 and did not affect the company’s equity share capital. No further regulatory approvals or corporate actions are pending as per the filing.